AUXLY CANNABIS GROUP INC (XLY.CA) Stock Fundamental Analysis
Canada • Toronto Stock Exchange • TSX:XLY • CA05335P1099
0.13 CAD
0 (0%)
Last: Feb 6, 2026, 07:00 PM
Overall XLY gets a fundamental rating of 6 out of 10. We evaluated XLY against 33 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of XLY get a neutral evaluation. Nothing too spectacular is happening here. XLY is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, XLY could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
- In the past year XLY was profitable.
- XLY had a positive operating cash flow in the past year.
- In the past 5 years XLY always reported negative net income.
- The reported operating cash flow has been mixed in the past 5 years: XLY reported negative operating cash flow in multiple years.
1.2 Ratios
- The Return On Assets of XLY (16.40%) is better than 96.97% of its industry peers.
- XLY has a better Return On Equity (26.28%) than 96.97% of its industry peers.
- The Return On Invested Capital of XLY (8.12%) is better than 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.4% | ||
| ROE | 26.28% | ||
| ROIC | 8.12% |
ROA(3y)-20.84%
ROA(5y)-18.51%
ROE(3y)-81.82%
ROE(5y)-60.99%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- XLY has a Profit Margin of 31.05%. This is amongst the best in the industry. XLY outperforms 96.97% of its industry peers.
- With an excellent Operating Margin value of 17.28%, XLY belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
- XLY's Gross Margin of 52.00% is fine compared to the rest of the industry. XLY outperforms 78.79% of its industry peers.
- In the last couple of years the Gross Margin of XLY has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.28% | ||
| PM (TTM) | 31.05% | ||
| GM | 52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.45%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- XLY has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- Compared to 1 year ago, XLY has more shares outstanding
- The number of shares outstanding for XLY has been increased compared to 5 years ago.
- The debt/assets ratio for XLY has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 0.01, we must say that XLY is in the distress zone and has some risk of bankruptcy.
- XLY has a Altman-Z score of 0.01. This is comparable to the rest of the industry: XLY outperforms 57.58% of its industry peers.
- XLY has a debt to FCF ratio of 4.16. This is a neutral value as XLY would need 4.16 years to pay back of all of its debts.
- XLY has a better Debt to FCF ratio (4.16) than 84.85% of its industry peers.
- A Debt/Equity ratio of 0.30 indicates that XLY is not too dependend on debt financing.
- XLY has a Debt to Equity ratio of 0.30. This is comparable to the rest of the industry: XLY outperforms 54.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 4.16 | ||
| Altman-Z | 0.01 |
ROIC/WACC1
WACC8.12%
2.3 Liquidity
- XLY has a Current Ratio of 1.93. This is a normal value and indicates that XLY is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of XLY (1.93) is comparable to the rest of the industry.
- XLY has a Quick Ratio of 1.05. This is a normal value and indicates that XLY is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of XLY (1.05) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.05 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 151.10% over the past year.
- XLY shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.38%.
- XLY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 71.07% yearly.
EPS 1Y (TTM)151.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%433.33%
Revenue 1Y (TTM)27.38%
Revenue growth 3Y13.43%
Revenue growth 5Y71.07%
Sales Q2Q%19.57%
3.2 Future
- Based on estimates for the next years, XLY will show a very strong growth in Earnings Per Share. The EPS will grow by 53.92% on average per year.
- Based on estimates for the next years, XLY will show a very strong growth in Revenue. The Revenue will grow by 22.57% on average per year.
EPS Next Y210.75%
EPS Next 2Y53.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year14.35%
Revenue Next 2Y10.97%
Revenue Next 3Y26.12%
Revenue Next 5Y22.57%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- XLY is valuated cheaply with a Price/Earnings ratio of 3.25.
- Based on the Price/Earnings ratio, XLY is valued cheaper than 93.94% of the companies in the same industry.
- When comparing the Price/Earnings ratio of XLY to the average of the S&P500 Index (27.93), we can say XLY is valued rather cheaply.
- A Price/Forward Earnings ratio of 12.87 indicates a correct valuation of XLY.
- 81.82% of the companies in the same industry are more expensive than XLY, based on the Price/Forward Earnings ratio.
- XLY is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.77, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.25 | ||
| Fwd PE | 12.87 |
4.2 Price Multiples
- XLY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. XLY is cheaper than 84.85% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of XLY indicates a somewhat cheap valuation: XLY is cheaper than 75.76% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.05 | ||
| EV/EBITDA | 5.86 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- XLY has a very decent profitability rating, which may justify a higher PE ratio.
- XLY's earnings are expected to grow with 53.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y53.92%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for XLY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:XLY (2/6/2026, 7:00:00 PM)
0.13
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)03-18 2026-03-18/amc
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners5.73%
Ins Owner ChangeN/A
Market Cap175.30M
Revenue(TTM)146.00M
Net Income(TTM)45.34M
Analysts80
Price Target0.26 (100%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1150%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.25 | ||
| Fwd PE | 12.87 | ||
| P/S | 1.2 | ||
| P/FCF | 11.05 | ||
| P/OCF | 9.44 | ||
| P/B | 1.02 | ||
| P/tB | 1.22 | ||
| EV/EBITDA | 5.86 |
EPS(TTM)0.04
EY30.77%
EPS(NY)0.01
Fwd EY7.77%
FCF(TTM)0.01
FCFY9.05%
OCF(TTM)0.01
OCFY10.59%
SpS0.11
BVpS0.13
TBVpS0.11
PEG (NY)0.02
PEG (5Y)N/A
Graham Number0.34
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.4% | ||
| ROE | 26.28% | ||
| ROCE | 11.28% | ||
| ROIC | 8.12% | ||
| ROICexc | 9.41% | ||
| ROICexgc | 11.05% | ||
| OM | 17.28% | ||
| PM (TTM) | 31.05% | ||
| GM | 52% | ||
| FCFM | 10.87% |
ROA(3y)-20.84%
ROA(5y)-18.51%
ROE(3y)-81.82%
ROE(5y)-60.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.45%
GM growth 5YN/A
F-Score7
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 4.16 | ||
| Debt/EBITDA | 1.42 | ||
| Cap/Depr | 25.18% | ||
| Cap/Sales | 1.85% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 51.64% | ||
| Profit Quality | 34.99% | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.05 | ||
| Altman-Z | 0.01 |
F-Score7
WACC8.12%
ROIC/WACC1
Cap/Depr(3y)27.93%
Cap/Depr(5y)61.49%
Cap/Sales(3y)4.52%
Cap/Sales(5y)11.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)151.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%433.33%
EPS Next Y210.75%
EPS Next 2Y53.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)27.38%
Revenue growth 3Y13.43%
Revenue growth 5Y71.07%
Sales Q2Q%19.57%
Revenue Next Year14.35%
Revenue Next 2Y10.97%
Revenue Next 3Y26.12%
Revenue Next 5Y22.57%
EBIT growth 1Y204.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year772.58%
EBIT Next 3Y106.86%
EBIT Next 5Y66%
FCF growth 1Y4857.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y201.87%
OCF growth 3YN/A
OCF growth 5YN/A
AUXLY CANNABIS GROUP INC / XLY.CA FAQ
What is the ChartMill fundamental rating of AUXLY CANNABIS GROUP INC (XLY.CA) stock?
ChartMill assigns a fundamental rating of 6 / 10 to XLY.CA.
Can you provide the valuation status for AUXLY CANNABIS GROUP INC?
ChartMill assigns a valuation rating of 9 / 10 to AUXLY CANNABIS GROUP INC (XLY.CA). This can be considered as Undervalued.
Can you provide the profitability details for AUXLY CANNABIS GROUP INC?
AUXLY CANNABIS GROUP INC (XLY.CA) has a profitability rating of 6 / 10.
Can you provide the financial health for XLY stock?
The financial health rating of AUXLY CANNABIS GROUP INC (XLY.CA) is 5 / 10.